Marksans Pharma Reports Strong Sales Growth Amid Score Adjustment in May 2025
Marksans Pharma has announced its financial results for the quarter ending March 2025, reporting net sales of Rs 708.46 crore, the highest in five quarters. The Profit After Tax for the past six months reached Rs 195.11 crore, reflecting a year-on-year growth of 20.79%.
Marksans Pharma, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results, declared on May 19, 2025, indicate a notable performance in several key areas.The company achieved net sales of Rs 708.46 crore for the quarter, marking the highest figure recorded in the last five quarters. This consistent growth in sales reflects a positive near-term trend. Additionally, the Profit After Tax (PAT) for the latest six months stands at Rs 195.11 crore, showcasing a year-on-year growth of 20.79%. This upward trajectory in PAT further underscores the favorable near-term outlook for the company.
However, it is important to note that there has been an adjustment in evaluation, with the score for Marksans Pharma declining to 9 from 11 over the past three months. This revision in its score highlights the dynamic nature of the company's financial assessment.
For those interested in further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
